An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
复制标题
DOI：
10.1164/rccm.201506-1063st
复制
发表时间：
2015-07-15
影响因子：
24.7
通讯作者：
Schuenemann, Holger J.
中科院分区：
文献类型：
--
作者：
Raghu, Ganesh;Rochwerg, Bram;Schuenemann, Holger J.
背景：本文件更新了美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会关于特发性肺纤维化治疗的指南。方法：进行系统评价，并在适当时进行荟萃分析，以总结与我们的问题相关的所有可用证据。使用 GRADE（建议、评估、制定和评价分级）方法对证据进行评估，然后由多学科小组进行讨论。采用预先确定的利益冲突管理策略，并由不冲突的小组成员专门制定、撰写和评分建议。结果：在考虑了效果估计的置信度、研究结果的重要性、治疗的理想和不良后果、成本、可行性、干预的可接受性以及对健康公平的影响后，提出了支持或反对特定治疗干预措施的建议。结论：小组制定并提供了支持或反对特发性肺病治疗干预措施的建议的理由纤维化。
Background: This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize all available evidence pertinent to our questions. The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a multidisciplinary panel. Predetermined conflict-of-interest management strategies were applied, and recommendations were formulated, written, and graded exclusively by the nonconflicted panelists.Results: After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications to health equity, recommendations were made for or against specific treatment interventions.Conclusions: The panel formulated and provided the rationale for recommendations in favor of or against treatment interventions for idiopathic pulmonary fibrosis.